" 333.120 
permitted combinations of active ingredients. 
the following combinations are permitted provided each active ingredient is present within the established concentration and in the specified dosage form, and the product is labeled in accordance with  333.160. 
(a) combinations of antibiotic active ingredients. (1) bacitracin-neomycin sulfate ointment containing, in each gram, 500 units of bacitracin and 3.5 milligrams of neomycin in a suitable ointment base. 
(2) bacitracin-neomycin sulfate-polymyxin b sulfate ointment containing, in each gram, in a suitable ointment base the following: 
(i) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin b; or 
(ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin b; 
(3) bacitracin-polymyxin b sulfate topical aerosol containing, in each gram, 500 units of bacitracin and 5,000 units of polymyxin b in a suitable vehicle, packaged in a pressurized container with suitable inert gases. 
(4) bacitracin zinc-neomycin sulfate ointment containing, in each gram, 500 units of bacitracin and 3.5 milligrams of neomycin in a suitable ointment base. 
(5) bacitracin zinc-neomycin sulfate-polymyxin b sulfate ointment containing, in each gram, in a suitable ointment base the following: 
(i) 400 units of bacitracin, 3 milligrams of neomycin, and 8,000 units of polymyxin b; or 
(ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin b; or 
(iii) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin b; or 
(iv) 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin b; 
(6) bacitracin zinc-polymyxin b sulfate ointment containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin b in a suitable ointment base. 
(7) bacitracin zinc-polymyxin b sulfate topical aerosol containing, in each gram, 120 units of bacitracin and 2,350 units of polymyxin b in a suitable vehicle, packaged in a pressurized container with suitable inert gases. 
(8) bacitracin zinc-polymyxin b sulfate topical powder containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin b in a suitable base. 
(9) neomycin sulfate-polymyxin b sulfate ointment containing, in each gram, 3.5 milligrams of neomycin and 5,000 units of polymyxin b in a suitable water miscible base. 
(10) neomycin sulfate-polymyxin b sulfate cream containing, in each gram, 3.5 milligrams of neomycin and 10,000 units of polymyxin b in a suitable vehicle. 
(11) oxytetracycline hydrochloride-polymyxin b sulfate ointment containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin b in a suitable ointment base. 
(12) oxytetracycline hydrochloride-polymyxin b sulfate topical powder containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin b with a suitable filler. 
(b) combinations of first aid antibiotic active ingredients and local anesthetic active ingredients. (1) bacitracin ointment containing, in each gram, 500 units of bacitracin and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient in a suitable ointment base. 
(2) bacitracin-neomycin sulfate-polymyxin b sulfate ointment containing, in each gram, in a suitable ointment base the following: 
(i) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient; or 
(ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient. 
(3) bacitracin-polymyxin b sulfate topical aerosol containing, in each gram, 500 units of bacitracin and 5,000 units of polymyxin b and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient in a suitable vehicle, packaged in a pressurized container with suitable inert gases. 
(4) bacitracin zinc-neomycin sulfate-polymyxin b sulfate ointment containing, in each gram, in a suitable ointment base the following: 
(i) 400 units of bacitracin, 3 milligrams of neomycin, 8,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient; or 
(ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient; or 
(iii) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient; or 
(iv) 500 units of bacitracin, 3.5 milligrams of neomycin, 10,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient; 
(5) bacitracin zinc-polymyxin b sulfate ointment containing, in each gram, 500 units of bacitracin, 10,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient in a suitable ointment base. 
(6) neomycin sulfate-polymyxin b sulfate cream containing, in each gram, 3.5 milligrams of neomycin, 10,000 units of polymyxin b, and any single generally recognized as safe and effective amine or caine-type local anesthetic active ingredient in a suitable vehicle. 

